Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Home
- Home
About BR&R
Biosimilar Approval Status
BR&R Product Profiles
- Abrilada
- Amjevita
- Avasola
- Byooviz
- Cyltezo
- Erelzi
- Eticovo
- Fulphila
- Fylnetra
- Hadlima
- Herzuma
- Hulio
- Hyrimoz
- Inflectra
- Kanjinti
- Mvasi
- Nivestym
- Nyvepria
- Ogivri
- Ontruzant
- Releuko
- Renflexis
- Retacrit
- Rezvoglar
- Riabni
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Yusimry
- Zarxio
- Ziextenzo
- Zirabev
Contact Us
The 2023 Biosimilars Market Report

$0.00 0 items

Stanton Mehr May 6, 2016June 19, 2018

Published by Stanton Mehr

View all posts by Stanton Mehr

Published May 6, 2016June 19, 2018

Post navigation

Previous Post Previous Post

Leave a ReplyCancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

SM Health Comm

Search for:

Recent Posts

Interchange or Change? December 4, 2023
CVS Caremark’s Formulary Changes: Eye Pain for Eylea November 28, 2023
When Will a Biosimilar Version of Xolair® be Available? November 17, 2023
A Busy Month for Biosimilar Adalimumab Product Updates November 8, 2023
First Biosimilar Interleukin Approved by the FDA: Amgen Wezlana™ Is Interchangeable with Stelara® November 1, 2023
Update on Coherus’ Quest for Neulasta OnPro® Competitor October 30, 2023
Celltrion Scores FDA Approval of SC Infliximab: Will Use of the IV Formulation Be Affected? October 24, 2023
A Biosimilar Mainstay Faces an ASP Cliff October 12, 2023
The Push and Pull of Buy and Bill for Biosimilars on the Medical Benefit October 9, 2023
Biosimilars, Generics, and the Sustainability Nexus October 6, 2023

Recent Comments

	Drug Manufacturers’… on The Inflation Reduction Act: R…
	Drug Manufacturers’… on Thirty Years of Exclusivity fo…
	Manjiri Kulkarni on What is Cordavis and Why Will…
	MK on Where’s Pfizer’s Adalimumab Bi…
	Vinay Patel on The Adalimumab Biosimilar Grea…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Top Posts & Pages

Interchange or Change?
Biosimilar Approval Status
CVS Caremark’s Formulary Changes: Eye Pain for Eylea
The Evolution of the Biosimilars Market
Twelve Potential Competitors and Counting: An Update of the Denosumab Biosimilar Pipeline
An Attempt to Eliminate the Interchangeability Designation
Two More Patent Settlements and Launch Dates for Ustekinumab Biosimilars
A Busy Month for Biosimilar Adalimumab Product Updates
Denosumab Biosimilar Competitors Gathering Data for February 2025 Launch
Contact Us

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

Twitter
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions

Copyright

Copyright 2013-2023 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.